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HTS, bottlenecks and databases  
Currently large pharmaceutical companies are undergoing selective disintegration, 
while contract research organizations (CROs) and academia are growing in influence, 
publicly-funded drug development programs are expanding, precompetitive efforts are 
increasing, along with a re-emergence of venture-backed biotechnology firms (1). These 
developments have created a dynamic ecosystem with pharma as smaller nodes in a 
complex network, in which collaborations have become an important business model. 
However, we are seeing a shift in focus away from early drug discovery, counter to what 
some have suggested is necessary for the industry to survive post disintegration (2). 
This is exemplified by the shift of high throughput screening (HTS) for drug 
discovery from a small number of major pharmaceutical companies to a larger number of 
academic and institutional laboratories in the US. This seems counter intuitive as some 
drugs and a large percentage of leads are discovered using HTS (3), yet there are also 
examples in which HTS fails, in particular antibacterial research and other areas (4, 5). 
Learning from the pharma experience with HTS is instructive. A recent study identified 
78 academic screening centers in the US focused on high risk drug targets, while there 
were major gaps for efficacy testing, drug metabolism, PK studies and the challenge of 
translation to the clinic (6), commonly termed the “valley of death”. These gaps 
incidentally are all skills that pharma is removing and outsourcing. This leaves only 
CROs and clinically affiliated institutes able to overcome this bottleneck. Another issue 
identified by researchers from Bayer indicates that literature data on potential drug targets 
is not reproducible (7). Translating more compounds to the clinic from HTS screening 
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centers, may indicate that many would likely fail without controlling for bias in pre-
clinical proof of concept studies and target-based discovery to improve clinical success 
(8). Taking HTS out of pharmaceutical companies has not achieved innovative 
breakthroughs. And yet, the US government through different agencies is investing 
heavily in large HTS initiatives such as ToxCast (9, 10), Tox21 (11), Molecular Libraries 
Probe Production Centers Network (MLPCN) (12), National Center for Translational 
Therapeutics (NCATS) (13), the LINCS project (14) alongside the institutional screening 
centers, with little apparent coordination or consideration of the outputs. We have 
concerns regarding simply using the HTS assays (and data) that were optimized to 
minimize “false negatives” for risk assessment purposes.  
A crowdsourcing evaluation of MLPCN probes suggested to us that academic 
screening may result in a large number of dubious leads when in a drug screening mode 
(12). All of the screening efforts are generating very large quantities of data and there 
would be an expectation that it is freely accessible, requiring databases that can handle 
structures and multiple bioactivity endpoints. Recent NIH funded efforts with the NPC 
browser (15) suggest this is not straightforward (16) and poor data quality will severely 
impact the cost effective but increasingly informatics dependent tools being used for 
repurposing efforts (17). In our opinion there needs to be independent assessment and 
curation of the data produced across the board before embarking on more investments. 
It is also unclear how such data is policed to make sure it goes out in a timely 
manner for maximal exposure. We are not aware of any funding agency mandating data 
to be published along with quality guidelines, although we have suggested  granting 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
96
1.
1 
: P
os
te
d 
2 
M
ar
 2
01
2
4 
 
bodies should have minimal quality standards for published data (16). An extension to 
this would be that all data generated from publicly funded research should be openly 
available, within a year of generation, in high quality internet databases.  
We think part of the current trend in terms of proliferation of HTS screening 
initiatives is due to lack of coordination of government agencies, creating duplication and 
overlap, as exemplified by numerous chemical databases in North America containing 
approved drugs (Table 1). The government agencies would argue that redundancy in 
funding mitigates risk, however if there is no sharing of data or experience ex post facto, 
then the risk of duplicative failure and unproductive expenditure increases. From what we 
see there is too little collaboration around databases, curation, data quality (16) or even 
openness across the board.   
There has been much discussion in the context of NCATS, about the urgent need 
to revamp how drugs are developed, brought to market faster and what incentives can be 
provided to generate treatments for neglected and rare diseases (13). We question 
however whether any government or academic institute as they currently stand can 
adequately pursue such goals when an entire industry is struggling with the same 
challenges. Many of the techniques proposed (13), just like HTS, will not dramatically 
impact the process alone  because this has not occurred in pharma.  
Public private partnerships and translational informatics 
This begs the question of how we can remove the bottlenecks impeding progress 
now. Academic groups could avoid the “valley of death”, by working more closely with 
CROs and virtual pharmas to do more preclinical and development studies, who in turn 
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will work with pharmas to purchase the most promising compounds.  To do this there 
needs to be an awareness of what research is going on in the screening centers, and they 
in turn should be aware of groups that can take their hits. 
There is general agreement that the key to breakthrough success is collaboration 
(18). There is also consensus that social networking can provide an effective platform for 
increasing collaboration in biomedical research (19), yet to date this has failed to take 
hold. The reason is fundamental: monetization of intellectual property (IP). There is no 
incentive for research organizations to disclose their current research in an open social 
networking forum where competitors have equal access. This is even true in academic 
research where investigators compete for funding. The key to success of this model of 
collaboration is the security of IP and the ability to selectively disclose IP to a valid 
potential partner in a secure way that results in a mutually equitable outcome for all 
parties (20). Research collaborations are currently most advanced in the areas of 
neglected diseases, where funding comes primarily from public sources, data is more 
open, and potential profits are low or nil. The same situation is true for rare diseases (21, 
22) and one would expect the creation of networks and ways to do more with less funding 
using collaborative software (18, 23) will be essential. In both neglected and rare diseases 
the partners are more likely to share IP because the monetary value of the IP ceases to be 
a barrier.  
Given that research organizations appear to be open to embracing a new paradigm 
of collaboration, how is one scientist to know what other work is currently ongoing in a 
specific therapeutic or disease area when this is private? The key areas for success in 
biomedical research collaborations are for organizations to be able to “identify best-in-
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class capability, evaluate opportunities presented by programs and understand the 
associated risks” (24). To date, there is a lack of support mechanisms to identify and 
foster collaborations, resulting in a time consuming hit-or-miss process that relies on 
networking, internet searching, and attending scientific conferences. New services (25) 
that provide a low cost, efficient means of finding targeted scientific connections for 
research and funding, while protecting intellectual property will be key to connect 
everyone with a role in drug discovery and development.  As virtual companies will have 
nowhere near the resources or experience of a big pharma, much more work will need to 
be performed in silico (17) as well as in a collaborative manner (18) to ensure likely 
success. Another way to look at this is that a new virtual team paradigm has the potential 
to innovate through disruption.    
There have been several collaborative public private partnerships (PPP) in Europe  
to share drug safety data (26), ontologies and models (27) and knowledge management of 
pharmacological data (28), all of which foster collaboration, as well as data sharing from 
industry and academia. In comparison the USA has nothing comparable currently 
ongoing in its research portfolio. Such shared knowledge could help virtual pharmas, 
academics and institutes alongside pre-competitive initiatives like those in informatics 
(29-32) to focus on the best ideas. The key challenge here is to ensure the delivery of 
tools or services to solve common problems to all parties involved and that there is 
coordination, progress and no overlap with the PPP initiatives described above. All of 
these efforts lower the cost of research and remove duplication of efforts. A direct 
example is the structure representation standards documented for the FDA’s substance 
registration system (33) whose recommendations have largely been adopted by ChEMBL 
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(34) and will be implemented into ChemSpider (35) to support the OpenPHACTS  
project (28) for pharmaceutical companies that are participating in this initiative.  
 As big pharma relies more on the CROs and academics, they will focus on 
translational informatics (integrated software solutions to manage the logistics, data 
integration and collaboration) and other efforts such as Pfizer’s ePlacebo. This uses 
placebo dosing data from previously executed clinical trials to augment or potentially 
supplant the need for placebo control groups in clinical trials. A cross-pharma data 
sharing consortium would dramatically impact the cost associated with clinical trial 
recruitment and execution of placebo dosing. In an effort to stimulate data sharing of this 
type the FDA has announced an overhaul of its IT infrastructure (36). A first step is the 
effort to make the historical clinical data in the FDA’s vaults public to be followed by a 
vast amount of de-identified post market surveillance data. By doing this, the FDA hopes 
that the open access movement will stimulate the creation of public private partnerships 
aimed at sharing data relevant to other drug development stages. Could they go further 
and mandate all de-identified clinical data be made public as part of the cost of doing 
business? Although some groups are pro (37) and others con (38) this approach could be 
universally useful for health research. We should be aware of potential barriers to data 
sharing and collaboration. Data and information silos exist at all levels of organizations. 
Allowing for data/information integration across silos is not a technological problem, 
regardless of issues of taxonomies and ontologies, but those will be much easier to 
surmount than the cultural, societal, and behavioral barriers to effective collaboration 
(18). Such non-technical issues generally inhibit translational data analysis on a broad 
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scale. With all the distributed research efforts we do not want to see creation of new data 
silos. 
Mining by swarm and finding the best collaborators 
While the FDA and the NHS (39) have discussed the ‘big data’ or ‘analytics’ 
future involving analysis of patient data. We are also moving into the era of drug safety 
analysis, drug repurposing and marketing by sentiment analysis using social media 
stream mining tools (40-42). Swarm intelligence is a new subfield of bio-inspired 
artificial intelligence offering solutions to complex problems like pooled health-related 
data from different organizations as well as real time data from social networks (43).  
Emerging and likely disruptive technologies that listen to the crowd passively do not 
appear to be on the agenda (36).   
In summary, if we are to remove bottlenecks we need to provide more confidence 
that lead compounds will have efficacy in vivo and be safe. Some of these aspects could 
be considered using predictive models already assembled and exclusive to the 
pharmaceutical companies. Sharing precompetitive data and models (44, 45), whether 
through a PPP or collaborations, could provide more confidence in the quality of the 
leads produced such that they will attract investment. At the same time the fringes of 
industry and academia may harbor the real innovators that should be funded to transform 
R&D. Both governments and pharmas could use software like Collaboration Finder (25) 
to find the best researchers to fund and collaborators to work with on strategic priorities. 
This would enable NIH to fund continuous innovation, rather than rebuilding academia in 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
96
1.
1 
: P
os
te
d 
2 
M
ar
 2
01
2
9 
 
the shape of big pharma.  Disruption of the pharmaceutical industry may begin by a 
fundamental rethink of how to reward collaborative researchers in any organization. 
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Table 1. North American small molecule databases containing FDA approved drugs 
 
Database 
name 
Funding  Content and details URL 
PubChem NIH >30M molecules includes 
FDA approved drugs 
http://pubchem.ncbi.nlm.nih.g
ov/ 
NPC 
Browser 
NIH ~10,000 compounds 
includes FDA approved 
drugs 
http://tripod.nih.gov/npc/ 
ToxCast EPA >1000 compounds includes 
some drugs and drug like 
molecules 
http://epa.gov/ncct/toxcast/ 
DailyMed FDA >31,942 labels – many 
labels for the same drug 
http://dailymed.nlm.nih.gov/da
ilymed/about.cfm 
ChemIDplus NIH > 295,000 structures 
including many FDA small 
molecule approved drugs 
http://chem.sis.nlm.nih.gov/ch
emidplus/ 
DrugBank Canadian 6707 drug entries including 
1436 FDA-approved small 
molecule drugs (this may be 
underestimated). 
http://www.drugbank.ca/ 
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